There
is sufficient intramuscular vaccinia immune globulin (IM-VIG)
stored at the CDC to serve approximately 600-800 adverse events
if appropriate recommendations are followed. New lots of intravenous
(IV-VIG) are being produced that conform to intravenous
standards. This IV-VIG will require new recommendations for
both dosage and preferred method of administration. The new
IV-VIG has a low level of aggregated protein, allowing it
to be used by either the IM or IV route.
|
 |
Intravenous
VIG will be most likely administered at a lower dose than
the intramuscular preparation. In preliminary studies IV-VIG
appears to be 5-10 times as potent when tested in animal models.
Consult the CDC
for up-to-date information on this new IV-VIG.
|
